Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3631 to 3645 of 8235 results

  1. Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (HTG521)

    Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors in rheumatoid arthritis. The tests are Promonitor, IDKmonitor, LISA-tracker, RIDASCREEN, MabTrack, and those used by Sanquin Diagnostic Services.

    HealthTech guidance
    Published
    10 July 2019
    View recommendations

    Sections for HTG521

  2. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (HTG401)

    Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.

    HealthTech guidance
    Published
    17 February 2016
    View recommendations

    Sections for HTG401

  3. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.

    HealthTech guidance
    Published
    10 December 2014
    View recommendations

    Sections for HTG360

  4. Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (HTG607)

    Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.

    HealthTech guidance
    Published
    27 January 2022
    View recommendations

    Sections for HTG607

  5. Alpha-Stim AID for anxiety disorders (HTG570)

    Evidence-based recommendations on Alpha-Stim AID for managing anxiety disorders.

    HealthTech guidance
    Published
    8 March 2021
    View recommendations

    Sections for HTG570

  6. The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury (HTG356)

    Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury.

    HealthTech guidance
    Published
    12 November 2014
    View recommendations

    Sections for HTG356

  7. Modular updates

    Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.

  8. Bisphosphonates for treating osteoporosis. Patient decision aid on bisphosphonates for treating osteoporosis

    Bisphosphonates for treating osteoporosis Patient decision aid What is osteoporosis and how can bisphosphonates help? Everyone's bones get weaker as...

  9. Dementia. Patient decision aid on antipsychotic medicines for treating agitation, aggression and distress in people living with dementia

    Decision aid for Dementia: assessment, management and support for people living with dementia and their carers c NICE 2018. All rights reserved....

  10. Medicines associated with dependence or withdrawal symptoms. Patient decision aid summary version on should I stop my benzodiazepine or z-drug?

    Should I stop my benzodiazepine or z-drug? Patient decision aid: summary Do not stop taking your benzodiazepine or z-drug suddenly What are...

  11. Speaking engagements

    Ask an expert from NICE International, part of the UK's National Institute for Health and Care Excellence, to speak at a healthcare event in your country

  12. Our role in the Innovative Licensing and Access Pathway (ILAP)

    The Innovative Licensing and Access Pathway (ILAP) is a unique initiative which works with medicine developers early on to help get new medicines to patients faster.

  13. Artificial intelligence (AI) at NICE

    Home What NICE does Digital health...

  14. Tools for building or evaluating an evidence base

    Tools for building or evaluating a medtech evidence base with NICE

  15. Fees for technology appraisals and highly specialised technologies

    NICE fees for technology appraisals and highly specialised technologies